Acasti Pharma Inc.

TSXV:ACST 주식 보고서

시가총액: CA$19.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Acasti Pharma 과거 수익 실적

과거 기준 확인 0/6

주요 정보

22.8%

수익 성장률

61.8%

EPS 성장률

Pharmaceuticals 산업 성장23.1%
매출 성장률43.1%
자기자본 수익률-17.8%
순이익n/a
최근 수익 업데이트31 Dec 2022

최근 과거 실적 업데이트

Recent updates

Acasti Pharma (CVE:ACST) Is In A Good Position To Deliver On Growth Plans

Mar 01
Acasti Pharma (CVE:ACST) Is In A Good Position To Deliver On Growth Plans

Acasti Pharma (CVE:ACST) Is In A Strong Position To Grow Its Business

Aug 17
Acasti Pharma (CVE:ACST) Is In A Strong Position To Grow Its Business

Is Acasti Pharma (CVE:ACST) In A Good Position To Invest In Growth?

Jan 12
Is Acasti Pharma (CVE:ACST) In A Good Position To Invest In Growth?

수익 및 비용 분석

Acasti Pharma 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

TSXV:ACST 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
31 Dec 220-17511
30 Sep 220-17510
30 Jun 220-1168
31 Mar 220-1076
31 Dec 210-1294
30 Sep 210-1182
30 Jun 210-1873
31 Mar 210-2074
31 Dec 200386
30 Sep 200-699
30 Jun 200-211012
31 Mar 200-26816
31 Dec 190-56723
30 Sep 190-46626
30 Jun 190-42529
31 Mar 190-39429
31 Dec 180-31425
30 Sep 180-34322
30 Jun 180-20317
31 Mar 180-17312
31 Mar 170-825
30 Nov 160-725
31 Aug 160-726
31 May 160-626

양질의 수익: ACST is currently unprofitable.

이익 마진 증가: ACST is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: ACST is unprofitable, but has reduced losses over the past 5 years at a rate of 22.8% per year.

성장 가속화: Unable to compare ACST's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: ACST is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (42.3%).


자기자본 수익률

높은 ROE: ACST has a negative Return on Equity (-17.83%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기